CHI3L1 and myeloid sarcoma: Additionally, immunosuppressive treatments such as mitoxantrone and natalizumab play potential roles in multiple sclerosis (MS) therapy by decreasing cerebrospinal fluid (CSF) levels of Chi3l1 [304].